Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1

Journal of Internal Medicine

Volumn 243, Issue 6, 1998, Pages 477-488

  Jensen, R T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Gastric carcinoid tumour; Gastrinoma; Islet tumour; Omeprazole

Indexed keywords

CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; CARCINOID; CONFERENCE PAPER; FEMALE; GASTRECTOMY; GASTRINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; ORAL DRUG ADMINISTRATION; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH TUMOR; ZOLLINGER ELLISON SYNDROME;

HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; SURVIVAL ANALYSIS; TREATMENT OUTCOME; ZOLLINGER-ELLISON SYNDROME;

EID: 0031861884     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00281.x     Document Type: Conference Paper

References (92)

1. Ballard HS, Frame B, Harstock RT. Familial endocrine adenoma-peptic ulcer disease. Medicine 1985; 43: 481-92.
2. Eberle F, Grun R. Multiple endocrine neoplasia, type I (MEN 1). Ergeb Inn Med Kinderheilkd 1981; 46: 76-149.
3. Sheppard BC, Norton JA, Doppman JL, Maton PN, Gardner JD, Jensen RT. Management of islet cell tumors in patients with Multiple Endocrine Neoplasia: a prospective study. Surgery 1989; 106: 1108-17.
4. Vasen HF, Lamers CB, Lips CJ. Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in the Netherlands. Arch Intern Med 1989; 149: 2717-22.
5. Norton JA, Jensen RT. Multiple endocrine neoplasia. In: DeVita VT, Hellman S, Rosenberg SA, eds Cancer: Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincott-Raven Publishers, 1997: 1723-9.
6. Benya RV, Metz DC, Venzon DJ, Fishbeyn VA, Strader DB, Orbuch M et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med 1994; 97: 436-44.
7. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, eds. The Pancreas: Biology, Pathobiology and Disease. 2nd edn, New York: Raven Press Publishing Co., 1993: 931-78.
8. Mignon M, Cadiot G, Rigaud D, Ruszniewski P, Jais P, Lehy T et al. Management of islet cell tumors in patients with multiple endocrine neoplasia type I. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. (Frontiers in Gastrointestinal Research Series.) Basel, Switzerland: S. Karger, 1995: 342-59.
9. Jensen RT, Norton JA. Endocrine tumors of the pancreas. In: Yamada T, Alpers BH, Owyang C, Powell DW, Silverstein FE, eds Textbook of Gastroenterology, 2nd edn. Philadelphia, PA. J.B. Lippincott Publishing Co., 1995: 2131-66.
10. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solda E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996; 20: 168-72.
11. Lehy T, Cadiot G, Mignon M, Ruszniewski P, Bonfils S. Influence of multiple endocrine neoplasia type I on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992; 33: 1275-9.
12. Norton JA, Jensen RT. Unresolved surgical issues in the management of patients with the Zollinger-Ellison syndrome. World J Surg 1991; 15: 151-9.
13. Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108: 1637-49.
14. Melvin WS, Johnson JA, Sparks J, Innes JT, Ellison EC. Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia. Surgery 1993; 114: 1183-8.
15. Stabile BE, Passaro Jr E. Benign and malignant gastrinoma. Am J Surg 1985; 49: 144-50.
16. Kloppel G, Willemar S, Stamm B, Hacki WH, Heitz PU. Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I. An immunocytochemical study of nine patients. Cancer 1986; 57: 1824-32.
17. Thompson NW, Lloyd RV, Nishiyama RH, Vinik Al Strodel WE, Allo MD et al. MEN 1 pancreas: a histological and immunohistochemical study. World J Surg 1984; 8: 561-74.
18. Grama D, Eriksson B, Martensson H, Cedermark B, Ahrën B, Kristoffersson A et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 1992; 16: 632-9.
19. Metz DC, Jensen RT, Bale AE, Skarulis MC, Eastman RC, Nieman L et al. Multiple endocrine neoplasia type I: clinical features and management. In: Bilezekian JP, Levine MA, Marcus R, eds. The Parathyroids. New York: Raven Press Publishing Co., 1994: 591-646.
20. Wank SA, Doppman JL, Miller DL, Collen MJ, Maton PN, Vinayek R et al. Prospective study of the ability of computerized axial tomography to localize gastrinomas in patients with Zollinger-Ellison syndrome. Gastroenterology 1987; 92: 905-12.
21. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 1996; 125: 26-34.
22. Sugg SL, Norton JA, Fraker DL, Metz DC, Pisegna JR, Fishbeyn V et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg 1993; 218: 138-44.
23. Norton JA, Doppman JL, Collen MJ, Hannon JW, Maton PN, Gardner JD et al. Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg 1986: 204: 468-79.
24. Jensen RT, Fraker DL. Zollinger-Ellison syndrome: Advances in treatment of the gastric hypersecretion and the gastrinoma. J Am Med Assoc 1994; 271: 1-7.
25. Ellison EH, Wilson SD. The Zollinger-Ellison syndrome: Reappraisal and evaluation of 260 registered cases. Ann Surg 1964; 160: 512-30.
26. Bordi C, Cocconi G, Togni R, Vezzadini P, Missale G. Gastric endocrine cell proliferation. Association with Zollinger-Ellison syndrome. Arch Pathol 1974; 98: 274-8.
27. Solcia E, Capella C, Fiocca R, Rindi G, Rosai J, Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type I multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 1990; 14: 503-13.
28. Norton JA, Cornelius MJ, Doppman JL, Maton PN, Gardner JD, Jensen RT. Effect of parathyroidectomy in patients with hyperparathyroidism. Zollinger-Ellison syndrome and multiple endocrine neoplasia type I. A prospective study. Surgery 1987; 102: 958-66.
29. McCarthy DM, Peikin SR, Lopatin RN, Long BW, Spiegel A, Marx S et al. Hyperparathyroidism a reversible cause of cimetidine-resistant gastric hypersecretion. Br Med J 1979; 1: 1765-6.
30. Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Jensen RT. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 1993; 17: 468-80.
31. Jensen RT, Metz, DC, Koviack PD, Feigenbaum KM. Prospective study of the long-term efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1993; 7 (Suppl. 1): 41-50.
32. Metz DC, Pisegna JR, Ringham GL, Feigenbaum KM, Koviack PD, Maton PN et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 1995; 38: 245-56.
33. Metz DC, Strader DB, Orbuch M, Koviach PD, Feigenbaum KM, Jensen RT. Use of omeprazole in Zollinger-Ellison: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7: 597-610.
34. Metz DC, Jensen RT. Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management (Frontiers in Gastrointestinal Research Series.) Basel: S. Karger, 1995: 240-57.
35. Hirschowitz BI, Mohnen J, Shaw S. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996; 10: 507-22.
36. Jensen RT, Collen MJ, McArthur KE, Howard JM, Maton PN, Cherner JA et al. Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric acid hypersecretory states. Am J Med 1984; 77 (5B): 90-105.
37. Vinayek R, Howard JM, Maton PN, Wank SA, Slaff JI, Gardner JD et al. Famotidine in the therapy of gastric hypersecretory states. Am J Med 1986; 81: 49-59.
38. Jensen RT. Basis for failure of cimetidine in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1984; 29: 363-6.
39. Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Feigenbaum KM, Koviack PD et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103: 1498-508.
40. Maton PN, Frucht H, Vinayek R, Wank SA, Gardner JD, Jensen RT. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology 1988; 94: 294-9.
41. Miller LS, Vinayek R, Frucht H, Gardner JD, Jensen RT, Maton PN. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 1990; 98: 341-6.
42. Raufman JP, Collins SM, Pandol SJ, Korman LY, Collen MJ, Cornelius MJ et al. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 1983; 84: 108-13.
43. Frucht H, Howard JM, Slaff JI, Wank SA, McCarthy DM, Maton PN et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome: a prospective study. Ann Intern Med 1989; 111: 713-22.
44. Maton PN, Vinayek R, Frucht H, McArthur KA, Miller LS, Saeed ZA et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989; 97: 827-36.
45. Termanini B, Gibril F, Stewart CA, Weber HC, Jensen RT. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996; 10: 61-71.
46. Saeed ZA, Norton JA, Frank WO, Young MD, Maton PN, Gardner JD et al. Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome. Gastroenterology 1989; 96: 1393-402.
47. Vinayek R, Hahne WF, Euler AR, Norton JA, Jensen RT. Parenteral control of gastric hypersecretion in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38: 1857-65.
48. Vinayek R, Frucht H, London JF, Miller LS, Stark HA, Norton JA et al. Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Gastroenterology 1990; 99: 10-16.
49. Stewart CA, Termanini B, Sutliff VE, Corleto VD, Weber HC, Gibril F et al. Management of Zollinger-Ellison syndrome in pregnancy. Am J Obstet Gynecol 1997; 176: 224-33.
50. McArthur KE, Richardson CT, Barnett CC, Eshaghi N, Smerud MJ, McClelland RN et al. Laparotomy and proximal gastric vagotomy in Zollinger-Ellison syndrome: results of a 16-year prospective study. Am J Gastroenterol 1996; 91: 1104-11.
51. Jensen RT. Should the 1996 citation for Zollinger-Ellison syndrome read: Acid-reducing surgery in aggressive resections out?' Am J Gastroenterol 1996; 91: 1067-70.
52. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112: 335-47.
53. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJB, Dop FJ, Reubi JC et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. Ann NY Acad Sci 1994; 733: 416-24.
54. de Kerviler E, Cadiot G, Lebtahi R, Faraggi M, le Guludec D, Mignon M. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. Eur J Nucl Med 1994; 21: 1191-7.
55. Jensen RT. Peptide therapy. Recent advances in the use of somatostatin and other peptide receptor agonists and antagonists. In: Lewis JH & Dubois A, eds. Current Clinical Topics in Gastrointestinal Pharmacology. Malden, MA, USA: Blackwell Science, Inc., 1997; 144-223.
56. Ruszniewski P, Amouyal P, Amouyal G, Cadiot G, Mignon M, Bernades P. Endocrine tumors of the pancreatic area: localization by endoscopic ultrasonography. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management (Frontiers in Gastrointestinal Research Series.) Basel: S. Karger, 1995: 258-67.
57. Thompson NW, Czako PF, Eritts LL, Bude R, Bansal R, Nostrant TT et al. Role of endoscopic ultrasonography in the localization of insulinomas and gastrinomas. Surgery 1994; 116: 1131-8.
58. Rosch T, Lightdale CJ, Botel JF, Boyce GA, Sivak MV Jr, Yasuda K et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326: 1721-6.
59. Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg 1994; 31: 1-156.
60. Doppman JL, Chang R, Fraker DL, Norton JA, Alexander R, Miller DL et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med 1995; 123: 269-73.
61. Strader DB, Doppman JL, Orbuch M, Fishbeyn VA, Benya RV, Jensen RT et al. Functional localization of pancreatic endocrine tumors. In: Mignon M, Jensen RT, eds. Frontiers of Gastrointestinal Research. Basel: Karger Publishing Co., 1995: 282-97.
62. Jensen RT, Gibril F, Termanini B. Strategic algorithm for neuroendocrine tumor localization based on recent advances and fiscal considerations. Yale J Biol Med 1998 (in press).
63. Cadiot G, Lebtahi R, Sarda L, Bonnaud G, Marmuse JP, Vissuzaine C et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 1996; 111: 845-54.
64. Doppman JL. Pancreatic endocrine tumors - the search goes on (Editorial). N Engl J Med 1992; 326: 1770-72.
65. Alexander HR, Fraker DL, Norton JA, Bartlett DL, Goebel SU, Serrano J et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg (in press).
66. Malagelada J, Edis AJ, Adson MA, Van Heerden JA, Go VLW. Medical and surgical options in the Management of patients with gastrinoma. Gastroenterology 1983; 84: 1524-32.
67. Akerstrom G. Surgical treatment of carcinoids and endocrine pancreatic tumours. Acta Oncol 1989; 28: 409-14.
68. Orbuch M, Doppman JL, Strader DB, Fishbeyn VA, Benya RV, Metz DC et al. Imaging for pancreatic endocrine tumor localization: recent advances. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. (Frontiers in Gastrointestinal Research Series.) Basel: S. Karger, 1995: 268-81.
69. Fraker DL, Jensen RT. Pancreatic endocrine tumors. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincott-Raven Publishers, 1997: 1678-704.
70. Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop AE et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type I and the Zollinger-Ellison syndrome. N Engl J Med 1990; 322: 723-7.
71. MacFarlane MP, Fraker DL, Alexander HR, Norton JA, Jensen RT. A prospective study of surgical resection of duodenal and pancreatic gastrinomas. Surgery 1995; 118: 973-80.
72. Donow C, Pipeleers-Marichal M, Schroder S, Stanun B, Heitz PU, Klöppel G. Surgical pathology of gastrinoma: site, size, multicentricity, association with multiple endocrine neoplasia type I, and malignancy. Cancer 1991; 68: 1329-34.
73. Deveney CW, Deveney KS, Stark D, Moss A, Stein S, Way LW. Resection of gastrinomas. Ann Surg 1983; 198: 546-53.
74. Mignon M, Jais P, Cadiot G, Yedder D, Vatier J. Clinical features and advances in biological diagnostic criteria for Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. (Frontiers in Gastrointestinal Research Series.) Basel: S. Karger, 1995: 223-39.
75. Metz DC, Kuchnio M, Fraker DL, Venzon DJ, Jaffe G, Jensen RT et al. Flow cytometry and Zollinger-Ellison syndrome: relationship to clinical course. Gastroenterology 1993; 105: 799-813.
76. Stadil F. Treatment of gastrinomas with pancreatoduoenectomy. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. (Frontiers in Gastrointestinal Research Series.) Basel: S. Karger, 1995: 333-11.
77. Zollinger RM, Ellison EC, O'Dorisio TM, Sparks J. Thirty years' experience with gastrinoma. World J Surg 1984; 8: 427-35.
78. Frucht H, Norton JA, London JF, Vinayek R, Doppman JL, Gardner JD et al. Detection of duodenal gastrinomas by operative endoscopic transillumination: a prospective study. Gastroenterology 1990; 99: 1622-7.
79. Ruszniewski P, Podevin P, Cadiot G, Marmuse JP, Mignon M, Vissuzaine C et al. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas 1993; 8: 295-304.
80. Thompson NW, Bondeson AG, Bondeson L, Vinik A. The surgical treatment of gastrinoma in MEN 1 syndrome patients. Surgery 1989; 106: 1081-5.
81. Fishbeyn VA, Norton JA, Benya RV, Pisegna JR, Venzon DJ, Metz DC et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med 1993; 119: 199-206.
82. Norton JA, Sugarbaker PH, Doppman JL, Wesley RA, Maton PN, Gardner JD et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg 1986; 203: 352-9.
83. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992; 112: 1024-31.
84. Arnold R, Frank M. Systemic chemotherapy for endocrine tumors of the pancreas: recent advances. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. (Frontiers in Gastrointestinal Research Series.) Basel: S. Karger, 1995: 431-8.
85. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430-8.
86. Pisegna JR, Slimak GG, Doppman JL, Strader DB, Metz DC, Fishbeyn VA et al. An evaluation of human recombinant alpha Interferon in patients with metastatic gastrinoma. Gastroenterology 1995; 105: 1179-83.
87. Cadiot G, Laurent-Puig P, Thuille B, Lehy T, Mignon M, Olschwang S. Is the multiple endocrine neoplasia type I gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome? Gastroenterology 1993; 105: 579-82.
88. Debelenko LV, Emmert-Buck MR, Zhuang Z, Epshteyn E, Moskaluk CA, Jensen RT et al. The MEN 1 gene locus is involved in the pathogenesis of gastric ECL-cell carcinoids in MEN 1 -ZES patients. Gastroenterology 1997; 113: 773-82.
89. Ahlman H, Kolby L, Lundell L, Olbe L, Wangberg B, Granerus G et al. Clinical management of gastric carcinoid tumors. Digestion 1994; 55: 77-85.
90. Gough DB, Thompson GB, Crotty TB, Donohue JH, Kvols LK, Carney JA et al. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg 1994; 18: 473-80.
91. Jensen RT. Gastrinoma as a model for prolonged hypergastrinemia in man. In: Walsh JH, ed., Gastrin, New York: Raven Press Publishing Co., 1993: 373-93.
92. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185-200.